Skip to main content
Erschienen in: International Journal of Hematology 5/2021

02.01.2021 | Original Article

Prevalence of and risk factors for urolithiasis in Croatian patients with hemophilia

verfasst von: Marijo Vodanović, Marko Lucijanić, Silva Zupančić Šalek, Ivan Pećin

Erschienen in: International Journal of Hematology | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Urolithiasis may be more prevalent in patients with hemophilia (PWH) than in age-matched non-hemophilic males. We conducted a cross-sectional evaluation of 92 adult PWH at University Hospital Center Zagreb. The primary objective was to investigate the frequency of urolithiasis in adult PWH, and the secondary objective was to determine associated risk factors. Urolithiasis was diagnosed by ultrasound and other patient- and hemophilia-related parameters were recorded. The prevalence of urolithiasis was significantly higher among PWH than the reported prevalence in the general Croatian population (10.9% vs 5.9%; P = 0.042). Similarly, the incidence of urolithiasis during the course of the disease was significantly higher than the estimated cumulative lifetime incidence of urolithiasis in the Croatian population (25% vs 12%; P = 0.001). Multivariate analysis showed that arterial hypertension, the presence of inhibitors, hypercalciuria and hyperbilirubinemia were independent predictors of current urolithiasis (P < 0.05), and that hematuria (P = 0.051) and prior urinary infections (P = 0.059) were also relevant factors.
Urolithiasis is a significant burden in adult PWH. Identifying associated risk factors might help in establishing strategies for earlier recognition and more successful prevention and treatment of urolithiasis.
Literatur
1.
Zurück zum Zitat Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-47.CrossRef Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-47.CrossRef
2.
Zurück zum Zitat Shapiro S, Makris M. Haemophilia and ageing. Br J Haematol. 2019;184(5):712–20.CrossRef Shapiro S, Makris M. Haemophilia and ageing. Br J Haematol. 2019;184(5):712–20.CrossRef
3.
Zurück zum Zitat Canaro M, Goranova-Marinova V, Berntorp E. The ageing patient with haemophilia. Eur J Haematol. 2015;94(Suppl 77):17–22.CrossRef Canaro M, Goranova-Marinova V, Berntorp E. The ageing patient with haemophilia. Eur J Haematol. 2015;94(Suppl 77):17–22.CrossRef
4.
Zurück zum Zitat Kulkarni R, Soucie JM, Evatt B. Hemophilia surveillance system project investigators. Renal disease among males with haemophilia. Haemophilia. 2003;9(6):703–10.CrossRef Kulkarni R, Soucie JM, Evatt B. Hemophilia surveillance system project investigators. Renal disease among males with haemophilia. Haemophilia. 2003;9(6):703–10.CrossRef
5.
Zurück zum Zitat Esposito P, Rampino T, Gregorini M, Fasoli G, Gamba G, Dal Canton A. Renal diseases in haemophilic patients: pathogenesis and clinical management. Eur J Haematol. 2013;91(4):287–94.PubMed Esposito P, Rampino T, Gregorini M, Fasoli G, Gamba G, Dal Canton A. Renal diseases in haemophilic patients: pathogenesis and clinical management. Eur J Haematol. 2013;91(4):287–94.PubMed
6.
Zurück zum Zitat Ghosh K, Jijina F, Mohanty D. Haematuria and urolithiasis in patients with haemophilia. Eur J Haematol. 2003;70(6):410–2.CrossRef Ghosh K, Jijina F, Mohanty D. Haematuria and urolithiasis in patients with haemophilia. Eur J Haematol. 2003;70(6):410–2.CrossRef
7.
Zurück zum Zitat Ranta S, Valta H, Viljakainen H, Mäkitie O, Mäkipernaa A. Hypercalciuria and kidney function in children with haemophilia. Haemophilia. 2013;19(2):200–5.CrossRef Ranta S, Valta H, Viljakainen H, Mäkitie O, Mäkipernaa A. Hypercalciuria and kidney function in children with haemophilia. Haemophilia. 2013;19(2):200–5.CrossRef
8.
Zurück zum Zitat Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european society of cardiology and the European society of hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953–2041.CrossRef Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european society of cardiology and the European society of hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953–2041.CrossRef
9.
Zurück zum Zitat Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–70.CrossRef Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–70.CrossRef
10.
Zurück zum Zitat Oguić R, Dimec D, Markić D. Urolitijaza-prevencija, dijagnostika i liječenje. Medicina. 2004;42(40):95–102. Oguić R, Dimec D, Markić D. Urolitijaza-prevencija, dijagnostika i liječenje. Medicina. 2004;42(40):95–102.
11.
Zurück zum Zitat Tucak A, Kalem T, Cvijetić S, Galić J, Prlić D, Zorić I, et al. The incidence and risk factors of urolithiasis in active working population of the Osijek community: an epidemiological study. Period Biol. 2000;102(4):431–5. Tucak A, Kalem T, Cvijetić S, Galić J, Prlić D, Zorić I, et al. The incidence and risk factors of urolithiasis in active working population of the Osijek community: an epidemiological study. Period Biol. 2000;102(4):431–5.
12.
Zurück zum Zitat Šerić V, Babić-Ivančić V, Marković M, Šerić V, Cvijetić Avdagić S, Füredi-Milhofer H. Važnost suradnje i interdisciplinarnoga pristupa u rješavanju problema urolitijaze: jučer, danas, sutra. Med Vjesn. 2010;42(3–4):19–31. Šerić V, Babić-Ivančić V, Marković M, Šerić V, Cvijetić Avdagić S, Füredi-Milhofer H. Važnost suradnje i interdisciplinarnoga pristupa u rješavanju problema urolitijaze: jučer, danas, sutra. Med Vjesn. 2010;42(3–4):19–31.
13.
Zurück zum Zitat Ranta S, Viljakainen H, Mäkipernaa A, Mäkitie O. Hypercalciuria in children with haemophilia suggests primary skeletal pathology. Br J Haematol. 2011;153(3):364–71.CrossRef Ranta S, Viljakainen H, Mäkipernaa A, Mäkitie O. Hypercalciuria in children with haemophilia suggests primary skeletal pathology. Br J Haematol. 2011;153(3):364–71.CrossRef
14.
Zurück zum Zitat Holme PA, Combescure C, Tait RC, Berntorp E, Rauchensteiner S, de Moerloose P; ADVANCE Working Group. Hypertension, haematuria and renal functioning in haemophilia—a cross-sectional study in Europe. Haemophilia. 2016;22(2):248–255. Holme PA, Combescure C, Tait RC, Berntorp E, Rauchensteiner S, de Moerloose P; ADVANCE Working Group. Hypertension, haematuria and renal functioning in haemophilia—a cross-sectional study in Europe. Haemophilia. 2016;22(2):248–255.
15.
Zurück zum Zitat Cappuccio FP, Strazzullo P, Mancini M. Kidney stones and hypertension: population based study of an independent clinical association. BMJ (Clinical Research ed). 1990;300(6734):1234–6.CrossRef Cappuccio FP, Strazzullo P, Mancini M. Kidney stones and hypertension: population based study of an independent clinical association. BMJ (Clinical Research ed). 1990;300(6734):1234–6.CrossRef
16.
Zurück zum Zitat Qvigstad C, Tait RC, de Moerloose P, Holme PA; ADVANCE Working Group. Hematuria in aging men with hemophilia: Association with factor prophylaxis. Res Pract Thromb Haemost. 2020;4(2):309–317. Qvigstad C, Tait RC, de Moerloose P, Holme PA; ADVANCE Working Group. Hematuria in aging men with hemophilia: Association with factor prophylaxis. Res Pract Thromb Haemost. 2020;4(2):309–317.
17.
Zurück zum Zitat Grossfeld GD, Carroll PR. Evaluation of asymptomatic microscopic hematuria. Urol Clin North Am. 1998;25(4):661–76.CrossRef Grossfeld GD, Carroll PR. Evaluation of asymptomatic microscopic hematuria. Urol Clin North Am. 1998;25(4):661–76.CrossRef
18.
Zurück zum Zitat Prentice CR, Lindsay RM, Barr RD, Forbes CD, Kennedy AC, McNicol GP, et al. Renal complications in haemophilia and Christmas disease. Q J Med. 1971;40(157):47–61.PubMed Prentice CR, Lindsay RM, Barr RD, Forbes CD, Kennedy AC, McNicol GP, et al. Renal complications in haemophilia and Christmas disease. Q J Med. 1971;40(157):47–61.PubMed
Metadaten
Titel
Prevalence of and risk factors for urolithiasis in Croatian patients with hemophilia
verfasst von
Marijo Vodanović
Marko Lucijanić
Silva Zupančić Šalek
Ivan Pećin
Publikationsdatum
02.01.2021
Verlag
Springer Singapore
Erschienen in
International Journal of Hematology / Ausgabe 5/2021
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-020-03064-9

Weitere Artikel der Ausgabe 5/2021

International Journal of Hematology 5/2021 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.